A multicentre, randomised, double blind, placebo controlled phase II study of subcutaneous interferon beta-1a in the treatment of patients with active rheumatoid arthritis


Published in: Annals of the Rheumatic Diseases

Citation for published version (APA):
A multicentre, randomised, double blind, placebo controlled phase II study of subcutaneous interferon beta-1a in the treatment of patients with active rheumatoid arthritis


Ann Rheum Dis 2005;64:64-69; originally published online 8 Jul 2004; doi:10.1136/ard.2003.020347

Updated information and services can be found at:
http://ard.bmj.com/cgi/content/full/64/1/64

These include:

References
This article cites 23 articles, 4 of which can be accessed free at:
http://ard.bmj.com/cgi/content/full/64/1/64#BIBL

5 online articles that cite this article can be accessed at:
http://ard.bmj.com/cgi/content/full/64/1/64#otherarticles

Rapid responses
You can respond to this article at:
http://ard.bmj.com/cgi/eletter-submit/64/1/64

Email alerting service
Receive free email alerts when new articles cite this article - sign up in the box at the top right corner of the article

Topic collections
Articles on similar topics can be found in the following collections

Drugs: musculoskeletal and joint diseases (345 articles)
Rheumatoid Arthritis (924 articles)

Notes

To order reprints of this article go to:
http://www.bmjjournals.com/cgi/reprintform

To subscribe to Annals of the Rheumatic Diseases go to:
http://www.bmjjournals.com/subscriptions/
A multicentre, randomised, double blind, placebo controlled phase II study of subcutaneous interferon beta-1a in the treatment of patients with active rheumatoid arthritis


Objective: To assess the efficacy of interferon beta (IFNβ) in combination with methotrexate in treatment of patients with rheumatoid arthritis.

Methods: 209 patients with active rheumatoid arthritis, who had been on methotrexate for at least six months and at a stable dose for four weeks before study entry, were randomised in double blind fashion to receive placebo (0.05 ml or 0.5 ml), IFNβ 2.2 μg (0.05 ml), or IFNβ 44 μg (0.5 ml), given subcutaneously three times weekly for 24 weeks. The primary efficacy measure was a change in radiological scores at week 24. The secondary endpoint was the proportion of patients who met the ACR 20% improvement criteria at the end of the study. Synovial biopsy specimens were obtained before and after treatment from a subset of patients. Immunohistochemistry was used to detect the presence of inflammatory cells and the results were measured by digital image analysis. Collagen crosslinks were measured in urine at different times throughout the study.

Results: Analysis of radiological scores and clinical variable showed no changes in any of the groups, and there were no differences between the groups. On microscopic analysis of synovial tissue there was no significant change in the scores for infiltration by inflammatory cells after IFNβ treatment. Urinary levels of collagen crosslinks were unchanged between the treatment groups.

Conclusions: At the doses tested, treatment with IFNβ three times weekly in combination with methotrexate did not have a clinical or radiological effect in patients with rheumatoid arthritis.
disease while on methotrexate to determine whether IFNβ-1a is effective in reducing radiological damage and arthritis activity.

METHODS

Patients

Patients over 18 years of age with a diagnosis of rheumatoid arthritis according to the American College of Rheumatology (ACR) criteria(17) were eligible for inclusion in the study if the duration of their active disease was more than six months and less than eight years. Patients were also required to have at least eight swollen joints, and to fulfil no less than three of the following criteria: at least eight tender joints; physician's global assessment of disease activity between 2 and 4 on a five point scale; patient's global assessment of disease activity between 2 and 4 on a five point scale; serum C reactive protein above 15 mg/dl.

Patients were required to have used methotrexate for six months or more, and to have followed a stable regimen (>7.5 mg/week) for at least four weeks before study entry. Patients who were on oral corticosteroids (<10 mg/day) or non-steroidal anti-inflammatory drugs (NSAIDs) were required to have been on a stable dose for at least four weeks before enrolment. Patients were required to have adequate bone marrow reserve, liver function, and renal function (haemoglobin ≥5.5 mmol/l, white blood cell count ≥3.5 × 10^9/l, platelet count ≥100 × 10^9/l; serum bilirubin, aspartate aminotransferase, alanine aminotransferase, and alkaline phosphatase ≤1.5 times the upper limit of normal values, and serum creatinine ≤150 µmol/l).

Women who were pregnant or lactating were excluded from the study, as were patients who had received biological agents or ciclosporin within the previous six months, had used a DMARD other than methotrexate within 28 days, or had used leflunomide within eight weeks of enrolment.

Study protocol

Patients were randomised to one of four treatment groups: 2.2 µg (0.05 ml) IFNβ-1a, 44 µg (0.5 ml) IFNβ-1a, placebo (0.05 ml), or placebo (0.5 ml). All treatments were given by subcutaneous injection three times weekly for 24 weeks. Patients remained on a stable dose of methotrexate. Both the patients and the assessors were blinded to the treatment given. As IFNβ side effects are easily recognised, physicians responsible for general patient management, including safety assessments, were different from those responsible for efficacy assessments. Patients gave written informed consent before entering the study and the study protocol was approved by the local medical ethics committee at each of the participating sites.

Safety and efficacy analyses

The primary efficacy measure was defined as the change from baseline radiological score at 24 weeks of treatment, based on the presumed mechanism of action of IFNβ on osteoclasts(14–16) and in line with previous observations showing that even modestly effective treatments may have a demonstrable protective effect on radiological joint damage after only 24 weeks of treatment.(18–20) Anteroposterior radiographs of the hands and feet were scored using the Van der Heijde modified Sharp score(19) by two independent blinded observers. Erosions in the feet were scored from 1 to 10, erosions in hands were scored from 1 to 5, and joint space narrowing was scored from 1 to 4. Scores were combined from hand and foot radiographs to provide a total score ranging from 0 to 448, with joint space narrowing scores ranging from 0 to 168 and erosion scores ranging from 0 to 280, with a maximum of 160 for the hands and 120 for the feet. The change in Van der Heijde x-ray scores was calculated by the differences between the scores at the end of treatment and the scores on the baseline radiographs.

Secondary efficacy end points were defined as a 20% improvement in the ACR criteria (ACR20) and a decrease in C reactive protein concentrations. Clinical assessment for disease activity was repeated at baseline, day 15, day 29, and then every four weeks until week 28. This included a 68 joint count for joint swelling and tenderness; physician’s and patient’s assessment of disease activity on a scale from 0 (asymptomatic) to 5 (severe symptoms); assessment of pain by visual analogue scale from 0 (no pain) to 10 (severe pain); quality of life (health assessment questionnaire) from 1 (no disability) to 3 (severe disability); and erythrocyte

---

Table 1  Patient demographics, clinical characteristics, and previous treatment at baseline (ITT population)

<table>
<thead>
<tr>
<th></th>
<th>Combined placebo group</th>
<th>IFNβ, 2.2 µg (n = 67)</th>
<th>IFNβ, 44 µg (n = 68)</th>
<th>All patients (n = 208)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Demographics</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Age (years)</td>
<td>53.6 (11.7)</td>
<td>53.7 (12.8)</td>
<td>52.0 (11.1)</td>
<td>53.1 (11.9)</td>
</tr>
<tr>
<td>Age range (years)</td>
<td>25.1 to 81.4</td>
<td>28.0 to 79.0</td>
<td>29.3 to 77.9</td>
<td>25.1 to 81.4</td>
</tr>
<tr>
<td>Female</td>
<td>63.8%</td>
<td>83.6%</td>
<td>83.8%</td>
<td>77.4%</td>
</tr>
<tr>
<td>Disease status</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Mean duration (years)</td>
<td>4.1 (2.4)</td>
<td>4.2 (2.7)</td>
<td>4.2 (2.7)</td>
<td>4.2 (2.6)</td>
</tr>
<tr>
<td>Duration range (years)</td>
<td>0.6 to 9.5</td>
<td>0.6 to 12.5</td>
<td>0.5 to 10.4</td>
<td>0.5 to 12.5</td>
</tr>
<tr>
<td>Rheumatoid factor positive</td>
<td>71.2%</td>
<td>65.2%</td>
<td>65.2%</td>
<td></td>
</tr>
<tr>
<td>Anti-CCP positive</td>
<td>54.8%</td>
<td>58.2%</td>
<td>55.9%</td>
<td></td>
</tr>
<tr>
<td>Functional class I</td>
<td>15.1%</td>
<td>13.4%</td>
<td>17.6%</td>
<td></td>
</tr>
<tr>
<td>Functional class II</td>
<td>67.5%</td>
<td>62.7%</td>
<td>72.1%</td>
<td></td>
</tr>
<tr>
<td>Functional class III</td>
<td>24.7%</td>
<td>22.4%</td>
<td>10.3%</td>
<td></td>
</tr>
<tr>
<td>Functional class IV</td>
<td>2.7%</td>
<td>1.5%</td>
<td>0</td>
<td></td>
</tr>
<tr>
<td>Concomitant MTX treatment</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>MTX dose (mg/week)</td>
<td>15.3 (4.6)</td>
<td>14.7 (5.5)</td>
<td>15.2 (5.1)</td>
<td>15.1 (5.0)</td>
</tr>
<tr>
<td>Length of MTX use (months)</td>
<td>19.0 (14.1)</td>
<td>16.4 (13.6)</td>
<td>17.1 (13.8)</td>
<td>17.6 (13.8)</td>
</tr>
</tbody>
</table>

Values are mean (SD) and range, or per cent.

CCP, cyclic citrullinated peptide; DMARD, disease modifying anti-rheumatic drug; ITT, intention to treat; MTX, methotrexate.
sensitivity rate (ESR) and C reactive protein measurement. In addition, rheumatoid factor, antibodies against cyclic citrullinated peptide (CCP), and anti-IFNβ antibodies were measured by enzyme linked immunosorbent assay (ELISA) at screening, at week 12, and at week 24.

Safety assessments were completed at every visit by an independent observer, and included an interview, examination of vital signs, inspection of injection sites, and evaluation of current laboratory data. The use of concomitant drug treatment was recorded throughout the study.

**Arthroscopy**

Some patients underwent arthroscopy of an inflamed knee joint under local anaesthesia at baseline and at week 24. Patients gave separate written informed consent for this procedure. Arthroscopies, tissue sampling, and storage were carried out as described previously in detail. All tissue samples were sent to the AMC, Amsterdam for immunohistochemical staining and digital image analysis.

**Immunohistochemical analysis**

Serial sections were stained with the following monoclonal antibodies (mAb): anti-CD68 (EBM11, Dako, Glostrup, Denmark), anti-CD55 (Clone-67, Serotec, Oxford, UK), and anti-CD3 (SK7, Becton-Dickinson, San Jose, California, USA). Sections with non-assessable tissue—defined by the absence of an intimal lining layer—were omitted before analysis. For control sections, the primary antibodies were omitted or irrelevant isotype matched mouse antibodies were applied. Staining was done according to a three step immunoperoxidase method as previously described.

**Digital image analysis**

The slides were evaluated by digital image analysis. All sections were coded and analysed in random order by an independent observer, who was blinded to the clinical data as described previously.

**Urinary analysis of hydroxy.pyridinium collagen crosslinks**

The presence of the collagen hydroxy.pyridinium crosslinks pyridinoline and deoxypyridinoline in urine is an indication of the breakdown of mature collagen. It has recently been shown that the total amount of pyridinium crosslinks excreted correlates with disease activity in rheumatoid arthritis. The urinary excretion of pyridinoline (released primarily from collagens type I and II of bone and cartilage) and deoxypyridinoline (released primarily from collagens type I and II of bone and dentin) was measured at baseline, at week 12, and at week 24. Urinary crosslink levels were investigated using gradient ion-paired reversed phase high performance liquid chromatography.

---

**Table 2** Summary of adverse events occurring in more than 5% of the patients

<table>
<thead>
<tr>
<th>Events</th>
<th>Placebo, 0.05 ml (n = 34)</th>
<th>Placebo, 0.5 ml (n = 39)</th>
<th>IFNβ, 2.2 µg (n = 67)</th>
<th>IFNβ, 44 µg (n = 68)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Injection site reaction</td>
<td>1 (3)</td>
<td>2 (5)</td>
<td>9 (13)</td>
<td>16 (24)</td>
</tr>
<tr>
<td>Flu-like symptoms</td>
<td>4 (12)</td>
<td>4 (10)</td>
<td>12 (18)</td>
<td>27 (40)</td>
</tr>
<tr>
<td>Headache</td>
<td>4 (12)</td>
<td>1 (3)</td>
<td>9 (13)</td>
<td>9 (13)</td>
</tr>
<tr>
<td>Fever</td>
<td>0</td>
<td>1 (3)</td>
<td>4 (6)</td>
<td>10 (15)</td>
</tr>
<tr>
<td>Fatigue</td>
<td>3 (9)</td>
<td>1 (3)</td>
<td>4 (6)</td>
<td>5 (7)</td>
</tr>
<tr>
<td>Rhinitis</td>
<td>5 (15)</td>
<td>4 (10)</td>
<td>11 (16)</td>
<td>4 (6)</td>
</tr>
<tr>
<td>Coughing</td>
<td>2 (6)</td>
<td>2 (5)</td>
<td>5 (7)</td>
<td>7 (10)</td>
</tr>
<tr>
<td>Upper respiratory tract infection</td>
<td>0</td>
<td>5 (13)</td>
<td>6 (9)</td>
<td>1 (1)</td>
</tr>
<tr>
<td>Nausea</td>
<td>4 (12)</td>
<td>0</td>
<td>5 (7)</td>
<td>6 (9)</td>
</tr>
<tr>
<td>Diarrhoea</td>
<td>2 (6)</td>
<td>2 (5)</td>
<td>3 (5)</td>
<td>4 (6)</td>
</tr>
<tr>
<td>SGPT increased</td>
<td>0</td>
<td>1 (3)</td>
<td>3 (5)</td>
<td>8 (12)</td>
</tr>
<tr>
<td>SGOT increased</td>
<td>0</td>
<td>1 (3)</td>
<td>2 (3)</td>
<td>8 (12)</td>
</tr>
<tr>
<td>Arthralgia</td>
<td>3 (9)</td>
<td>1 (3)</td>
<td>2 (3)</td>
<td>5 (7)</td>
</tr>
<tr>
<td>Rheumatoid arthritis aggravated</td>
<td>5 (15)</td>
<td>5 (13)</td>
<td>17 (25)</td>
<td>19 (28)</td>
</tr>
<tr>
<td>Increased ESR</td>
<td>2 (6)</td>
<td>3 (8)</td>
<td>6 (9)</td>
<td>11 (16)</td>
</tr>
<tr>
<td>Increased CRP</td>
<td>11 (32)</td>
<td>6 (15)</td>
<td>10 (15)</td>
<td>11 (16)</td>
</tr>
</tbody>
</table>

Values are n (%).

CRP, C reactive protein; ESR, erythrocyte sedimentation rate; IFNβ, interferon beta; SGOT, aspartate aminotransferase; SGPT, alanine aminotransferase.
Statistical analysis
The primary efficacy dataset was defined as all randomised patients for whom there were two sets of evaluable hand and foot x rays (one set for baseline and one set for week 24; patients who withdrew from study between week 12 and week 24 had x rays as soon as possible after the last injection of study drug) and who were not major protocol violators. The intention to treat (ITT) population comprised 208 patients who received at least one dose of study drug. For statistical analysis, the two placebo groups were combined and compared with the groups having IFNβ-1a treatment. The results before and after treatment were compared by paired t test. Two non-parametric tests were used: the Kruskal–Wallis test for several group means (comparing clinical assessment and histological scores in more than two treatment groups), followed by the Mann–Whitney U test for comparison of two groups. For the ACR20 response, non-completers of the study were considered to be non-responders.

RESULTS
Patient characteristics and disposition
In all, 209 patients were recruited from 30 centres in 10 countries during an eight month period. Their baseline characteristics are summarised in table 1. The mean (SD) age of the 161 women (77%) and 47 men (23%) was 53 (11.9) years. The median duration of disease was 3.6 years (range 0.5 to 12.5 years); 140 patients (67%) were rheumatoid factor positive and 117 (56%) had antibodies against CCP. All patients had active disease at study entry; 165 (79%) were in functional class I or II, 40 (19%) were in class III, and three (1%) were in class IV. There were no statistically significant differences between the treatment groups with regard to dose or duration of methotrexate.

All 209 patients were randomised and 208 received treatment (ITT population). The disposition of the patients across the study groups is shown in fig 1.

Safety and tolerability
Injection site reactions were the most commonly reported adverse events during the study and affected a higher proportion of patients on active treatment than on placebo. Similarly, general disorders including flu-like symptoms, headache, and increased ESR occurred at a higher frequency in the active treatment groups than in the placebo groups (table 2). Aggravated rheumatoid arthritis and raised C reactive protein concentrations were reported in a substantial number of patients in each treatment group, and there was a comparable incidence of respiratory system and gastrointestinal disorders in all treatment groups. A marginally increased incidence of raised liver enzymes appeared to be associated with the administration of IFNβ 44 µg. All events were of a mild or moderate nature, and severity was comparable between active and control groups: 10 patients in the IFNβ 44 µg group developed liver enzyme elevations of mild severity and six of moderate severity; five patients in the IFNβ 2.2 µg group developed elevations of mild severity and two of moderate severity; two patients in the placebo groups developed elevations of moderate severity.

More withdrawals were caused by adverse events in the 44 µg group (11 patients) than in the other treatment groups (two patients in the IFNβ 2.2 µg group and four in the placebo groups). In the 44 µg group, injection site reactions caused the most adverse event related withdrawals (seven patients); however, in the other groups no withdrawals were caused by injection site reactions. Flu-like symptoms, aggravated rheumatoid arthritis, and increased liver enzyme levels each caused the withdrawal of two patients from the total study population. Two patients tested positive for neutralising antibodies against IFNβ-1a at the end of treatment: both were receiving IFNβ 44 µg.

Clinical efficacy
There was no significant reduction in the progression of joint damage associated with treatment with IFNβ-1a at either of the doses tested compared with the control groups, as measured by the change from baseline in Van der Heijde x ray scores of the hands and feet (table 3). The 56 evaluable patients in the control group showed a median change of 1 (range –12 to 17), 48 patients in the 2.2 µg IFNβ group showed a median change of 1 (range –3 to 12), and the 37 evaluable patients in the 44 µg IFNβ group showed a median change of 0 (range –5 to 47). There were no statistically significant differences between the median ACR20 and ACR50 response rates between patients on active therapy and those in the control groups (fig 2).

Immunohistochemical analysis
Twenty five patients underwent synovial biopsy procedures, of whom 23 had results at baseline and 20 at the end of treatment (only 19 patients had both). The results of the immunohistochemical analysis are shown in table 4. After IFNβ 44 µg treatment there was a decrease in the number of...
and 75 (35 to 254) and 67 (39 to 188) with IFN 44 g treatment and the difference in IFN 44 g treatment reported here is in clear contrast to previous animal work.

**Collagen crosslinks analysis**

There were no significant differences in urinary levels of the collagen crosslinks pyridinoline and deoxypyridinoline between patients treated with IFN β and those treated with placebo. Levels of crosslinks were similar before treatment and after treatment in all groups. Thus median (range) pyridinoline concentrations, in nmol/μmol creatinine, were 69 (27 to 233) at baseline and 70 (28 to 234) at week 24 with placebo; 75 (24 to 194) and 76 (30 to 212) with IFN 2.2 μg; and 75 (35 to 254) and 67 (39 to 188) with IFN 44 μg. Median (range) deoxypyridinoline concentrations, also in nmol/μmol creatinine, were 17 (7 to 170) at baseline and 16 (5 to 88) at week 24 with placebo; 19 (9 to 113) and 21 (9 to 38) with IFN 2.2 μg; and 18 (6 to 47) and 16 (9 to 65) with IFN 44 μg.

**DISCUSSION**

We report the results of a double blind, placebo controlled trial that evaluated the efficacy of subcutaneous IFNβ-1a on radiological and clinical variables in patients with rheumatoid arthritis who were concomitantly receiving methotrexate. Treatment with IFNβ-1a for 24 weeks was not associated with clinical or radiological improvement, neither was there a statistical change in biomarkers.

The absence of improvement in radiological scores after IFNβ treatment reported here is in clear contrast to previous in vitro and animal studies. In these studies, IFNβ has been shown to partly inhibit osteoclastogenesis and in consequence to reduce the development of erosive disease in CIA models.15 16 18 The discrepancy between the present study and previous animal work might relate to the mode of administration and the difference in IFNβ-1a dosages used. In the present study IFNβ was given three times weekly, following the regular treatment regimen in multiple sclerosis patients. In contrast, successful preclinical studies were done either with gene therapy, which leads to continuous IFNβ release, or with daily IFNβ injections at a dose of 2.5 μg/mouse/day.

Although IFNβ is known to have a short half life, we chose not to use daily injections with higher IFNβ concentrations because it was anticipated that this would be less tolerable to the patients. It is possible that more frequent injections, higher dosages, or the use of compounds with a longer half life is required to induce clinically meaningful effects in patients with rheumatoid arthritis. In addition, we cannot exclude the possibility that we were unable to detect a modest protective effect on joint integrity in the light of the relatively short duration of the study.

There was a surprisingly high rate of discontinuation in our study. This was most pronounced in the IFNβ 44 μg treatment group. The most common reason for discontinuation was lack of efficacy—all treatment groups had similar percentages of drop out for this reason. However, withdrawals caused by adverse events such as injection site reactions and flu-like symptoms were more common in the 44 μg IFNβ group than in the other treatment groups. The high rate of withdrawal contrasts with results from placebo controlled trials with IFNβ-1a in multiple sclerosis.2 This discrepancy may be explained by a difference in disease pathogenesis or differences in the study populations. The most likely explanation is, however, the use of drug titration at the start of treatment. In trials of IFNβ in multiple sclerosis, the study drug is usually titrated over the first month from 20% to 50% and subsequently to full dose of treatment to reduce the incidence of adverse events.4 In the present study patients started treatment with their full dose of IFNβ-1a.

Previous work has shown that analysis of serial synovial tissue samples in patients with rheumatoid arthritis is likely to reflect the biological effects of the treatment given; for example, patients who received either placebo or unsuccessful treatment with recombinant human IL10 did not show any significant synovial changes.3 19 20 In contrast, beneficial clinical effects of anti-TNFα therapy are associated with decreased infiltration of synovial tissue by inflammatory cells.21 Consistent with this, our data show that persistent disease activity is associated with unchanged synovial inflammation in serial biopsy specimens in IFNβ treated rheumatoid patients. An earlier study suggested a modest reduction in CD3 positive T cells after one month of IFNβ treatment in synovial tissue of 11 rheumatoid patients. However, it was noted in the same study that the number of CD3 positive T cells returned to baseline levels after three months of treatment.11

In conclusion, the results of this study show that there was no apparent reduction in the progression or activity of rheumatoid arthritis compared with placebo when methotrexate treatment was supplemented with IFNβ-1a in doses of either 44 μg or 2.2 μg over 24 weeks.

**ACKNOWLEDGEMENTS**

We are pleased to acknowledge the assistance and cooperation of our colleagues. We also thank the following investigators and their colleagues: B Bresnihan, Dublin, Ireland; H Dinant, Amsterdam, Netherlands; B Dijkstra, Amsterdam, Netherlands; P Emery, Leeds, UK; M Kraan, Amsterdam, Netherlands; R Inman, Toronto, Canada; C Jackson, Salt Lake City, USA; J Kaltwasser, Frankfurt, Germany; E Keystone, Toronto, Canada; P Maddison, Bath, UK; W Maksymowycz, Edmonton, Canada; B Harauyi, Montreal, Canada; M Molla, Madrid, Spain; B Kidd, London, UK; N Wei, Maryland, USA; M Molloy, Cork, Ireland; L Moreland, Birmingham, Alabama, USA; R Reau, Ratingen, Germany; R Rodriguez, Sevilla, Spain; D van Schaardenburg.

---

**Table 4** Changes from baseline in synovial tissue indices in the 19 patients who underwent arthroscopy

<table>
<thead>
<tr>
<th>Cell type</th>
<th>Combined placebo groups</th>
<th>IFNβ, 2.2 μg</th>
<th>IFNβ, 44 μg</th>
</tr>
</thead>
<tbody>
<tr>
<td>CD68+ macrophages</td>
<td>–12 (212 to 150), n=7</td>
<td>85 (59 - 515), n=5</td>
<td>–46 (320 to 111), n=7</td>
</tr>
<tr>
<td>Intimal lining CD68+ macrophages</td>
<td>–22 (169 to 160), n=7</td>
<td>22 (143 to 109), n=5</td>
<td>–7 (228 to 233), n=7</td>
</tr>
<tr>
<td>CD55+ fibroblasts</td>
<td>1 (347 to 290), n=7</td>
<td>106 (94 to 293), n=5</td>
<td>1 (370 to 532), n=7</td>
</tr>
<tr>
<td>CD3+ lymphocytes</td>
<td>–4 (466 to 517), n=7</td>
<td>–2 (356 to 32), n=5</td>
<td>–4 (253 to 65), n=7</td>
</tr>
</tbody>
</table>

Values are median per cent change (range). Data represent total cell count in 18 high power fields corrected for the percentage of actual tissue in the analysed area for cellularity, CD68+ macrophages, CD55+ fibroblast-like synoviocytes and a slight decrease in CD3+ T cells; however, no statistically significant differences were detected when compared with placebo.
Amsterdam, Netherlands; M Smith, Melbourne, Australia; K Vos, Amsterdam, Netherlands; B Williams, Cardiff, UK.

Authors’ affiliations

J van Holten, P P Tak, Academic Medical Centre, University of Amsterdam, Amsterdam, Netherlands

K Pavelka, J Vencovsky, Institute of Rheumatology, Prague, Czech Republic

H Stahl, Institute of Clinical Immunology and Transfusion Medicine, University of Leipzig, Leipzig, Germany

B Rozman, University Medical Centre, Ljubljana, Slovenia

M Genovese, Division of Immunology and Rheumatology, Stanford University Medical Center, Palo Alto, California, USA

A J Kivitz, Alloma Center for Clinical Research, Dunscaville, Pennsylvania, USA

J Alvaro, Hospital de la Princesa, Madrid, Spain

G Nuki, University of Edinburgh, Edinburgh, Scotland, UK

D E Furst, UCLA Medical School, Los Angeles, California, USA

G Herrero-Beaumont, Universidad Autonoma de Madrid, Madrid, Spain

J B McInnes, University of Glasgow, Glasgow, UK

P Musikic, Serono-International, Geneva, Switzerland

REFERENCES


10 Coclet-Ninin J, Dayer JM, Burger D. Interferon-beta not only inhibits interleukin-1beta and tumor necrosis factor-alpha but stimulates interleukin-1 receptor antagonist production in human peripheral blood mononuclear cells. Eur Cytokine Netw 1997; 8:345–9.


